When should lipoprotein(a) and apolipoprotein B testing be ordered in adult patients?

When to Order Lipoprotein(a) and Apolipoprotein B

Lipoprotein(a) Testing

Measure Lp(a) at least once in every adult's lifetime as part of cardiovascular risk assessment. 1, 2, 3

Universal Screening Approach

• All adults should have Lp(a) measured once during their lifetime, as recommended by the 2021 Canadian Cardiovascular Society and 2024 National Lipid Association guidelines 1, 2, 3
• Single measurement is sufficient because Lp(a) levels are >90% genetically determined and remain stable throughout adult life, unaffected by age, fasting status, or lifestyle 2, 4
• No repeat testing needed unless previously measured in childhood or early adulthood 5, 6, 2

Priority Groups for Lp(a) Testing

Even with universal screening recommendations, these groups warrant immediate measurement if not yet tested:

• Family history of premature ASCVD (men <55 years, women <65 years) 5, 7
• Personal history of ASCVD not explained by traditional risk factors 5, 6, 5
• Familial hypercholesterolemia (clinically suspected or genetically confirmed) 8, 4
• Recurrent or progressive ASCVD despite optimal lipid-lowering therapy 9, 3, 10
• Intermediate 10-year ASCVD risk (7.5-19.9%) when considering statin initiation 5, 7
• First-degree relatives of patients with elevated Lp(a) through cascade screening 3, 4

Risk Thresholds

• Lp(a) ≥50 mg/dL (≥125 nmol/L) constitutes a risk-enhancing factor that warrants intensified risk factor management 5, 7, 2
• Lp(a) ≥100 mg/dL (≥214 nmol/L) is associated with ≥2-fold increase in major adverse cardiovascular events 2
• Lp(a) <30 mg/dL (<75 nmol/L) indicates low risk 3

Clinical Action Based on Lp(a) Results

When Lp(a) is elevated (≥50 mg/dL):

• Intensify LDL-C lowering as the primary therapeutic target, since no specific Lp(a)-lowering therapy is currently approved 5, 6, 3, 4
• Lower statin initiation threshold in primary prevention, especially when LDL-C is 135-193 mg/dL 2
• Consider PCSK9 inhibitors in secondary prevention patients, as these agents reduce Lp(a) by 20-30% and independently lower cardiovascular events 2, 4
• Implement aggressive lifestyle modification including smoking cessation, diet, exercise, and management of hypertension and diabetes 2, 3
• Consider coronary artery calcium scoring to refine risk assessment in borderline or intermediate-risk individuals 6, 2

---

Apolipoprotein B Testing

Measure apoB when triglycerides are ≥200 mg/dL (≥2.3 mmol/L) or when more accurate assessment of atherogenic particle burden is needed. 5, 1

When to Order ApoB

• Triglycerides >150 mg/dL (>1.7 mmol/L), where apoB or non-HDL-C is preferred over LDL-C 1
• Triglycerides ≥200 mg/dL (≥2.3 mmol/L) as a relative indication for measurement 5, 7
• LDL-C <70 mg/dL (<1.8 mmol/L) when Friedewald calculation becomes unreliable 5
• Hypertriglyceridemia to determine whether the condition is atherogenic 5
• Metabolic syndrome or diabetes where discordance between LDL-C and particle number is common 1, 11

Risk Threshold

• ApoB ≥130 mg/dL corresponds to LDL-C ≥160 mg/dL and constitutes a risk-enhancing factor 5, 7
• Persistent elevation of apoB should be considered a risk-enhancing factor even when LDL-C appears controlled 5

Advantages of ApoB Over LDL-C

• More accurate in hypertriglyceridemia because it captures all atherogenic particles including VLDL, remnants, and LDL 5, 1, 11
• Superior risk prediction compared to LDL-C, particularly when triglyceride-rich lipoproteins are elevated 1, 11
• Not affected by fasting status unlike calculated LDL-C 1

Practical Considerations

• Extra expense and variable laboratory reliability limit routine use 5
• The 2018 AHA/ACC guideline advises against routine apoB measurement, preferring non-HDL-C instead 1
• The 2021 Canadian and 2019 European guidelines recommend apoB or non-HDL-C as preferable to LDL-C when triglycerides are elevated 1

Clinical Action Based on ApoB Results

When apoB is elevated (≥130 mg/dL):

• Intensify statin therapy to achieve greater LDL-C and apoB reduction 5, 1
• Consider adding ezetimibe or PCSK9 inhibitors if apoB remains elevated on statin therapy 1
• Use apoB as a secondary target after LDL-C goals are achieved 12

---

Key Differences Between Lp(a) and ApoB Testing

• Lp(a) is measured once in a lifetime because it is genetically determined and stable 2, 4
• ApoB may require serial monitoring similar to LDL-C when used to guide therapy 5
• Lp(a) has no modifiable lifestyle factors; management focuses on intensifying other risk factors 2, 3, 4
• ApoB responds to lipid-lowering therapy and can be used to monitor treatment response 5, 1